UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
BIOTECHNOLOGY

Kuros Biosciences

The future of spinal fusions is right here

Kuros Biosciences logo

Kuros Biosciences

BiotechnologySwitzerland

The future of spinal fusions is right here

Visit Website

About Kuros Biosciences

Kuros Biosciences pioneers biologic bone graft technologies designed to advance bone healing through the combination of innovation and clinical evidence. The Swiss-headquartered biotech company is listed on the SIX Swiss Exchange under the ticker KURN, with operations extending to the Netherlands and the United States.

Central to its offering is the MagnetOs product family, a portfolio of bone graft solutions available in multiple formulations. For spinal applications, the range includes MagnetOs Easypack Putty, MagnetOs MIS, MagnetOs Flex Matrix, MagnetOs Putty and MagnetOs Granules. A parallel line addresses extremity indications, with products sharing the same core mechanism of action. The breadth of these formulations reflects a commitment to addressing both surgical access requirements and diverse anatomical targets across orthopaedic settings.

Kuros supports clinicians and procurement specialists through a dedicated Evidence Hub, providing access to clinical research, a searchable bibliography and a global research summary. The company also enables direct engagement with clinical, medical and scientific affairs through an expert consultation pathway, signalling its orientation toward evidence-based adoption within the orthopaedic biologics sector.

The leadership structure includes a board of directors, a clinical and scientific affairs team, and specialist strategic advisory boards for both the spine and extremities segments, reflecting the depth of clinical governance brought to product development and post-market activities.

Further information is available at kurosbio.com.

Areas of Expertise

Medical DevicesSpinal Surgery

Services & Capabilities

Medical DevicesSpinal Surgery
Similar Companies

More in Biotechnology

E

Elasmogen Ltd

Founded in Aberdeen, Scotland, Elasmogen Ltd is a privately held biopharmaceutical company advancing a proprietary platform of next-generation biologics called soloMERs. These engineered single-domain antibody-based molecules are designed to combine biologic precision with the localised activity of small molecules, drawing on an ADC-inspired conjugate strategy that the company believes can deliver safer and more effective treatment than conventional biologics alone. Lead Programme: ELN28 for Hidradenitis Suppurativa Elasmogen's lead clinical candidate, ELN28, is a first-in-class dual-acting soloMER conjugate targeting Hidradenitis Suppurativa (HS), a chronic and debilitating inflammatory skin condition characterised by painful lesions, deep nodules, abscesses, skin tunnels, and scarring. HS is recognised as a major unmet need: current treatments offer only partial benefit, and the disease carries a pronounced psychosocial burden in addition to its physical impact. ELN28 combines two clinically validated agents in a single construct, aiming to address both the inflammatory drivers and tissue pathology of HS with greater precision than existing monotherapies. Platform and Pipeline Ambitions Beyond HS, Elasmogen's soloMER platform has potential application across a broader range of immune-mediated inflammatory diseases and solid-tumour oncology indications. The company's stated vision is to lead the next wave of innovation in immune-mediated disease, developing therapies that redefine clinical practice. Elasmogen operates at the intersection of biologic drug development and novel conjugate chemistry, positioning the soloMER format as a modular, adaptable tool for addressing conditions where existing biologics fall short. Further information is available at elasmogen.com.

View profile
A

Adrestia Therapeutics

Founded in 2018 by Professor Steve Jackson in partnership with Ahren Innovation Capital, Adrestia Therapeutics was a Cambridge-based biotech that pioneered a novel approach to treating intractable genetic diseases through what it called synthetic rescue. The company's Disease Rebalancing Platform mapped gene interaction networks across the human genome to identify molecular partners capable of restoring function in damaged, diseased, or dying cells, creating a systematic atlas of therapeutic opportunities that conventional target-selection methods could not reach. Therapy Areas and Pipeline Adrestia concentrated its early programmes on neurological, neuromuscular, and cardiomyopathic diseases. A notable collaboration with Dr Sarah Tabrizi at University College London focused on Huntington's disease, while a partnership with Proteros Biostructures in Munich accelerated the identification of first-in-class small-molecule candidates across multiple targets. The company also engaged Proteros to support structural biology and drug-discovery chemistry for its lead programmes. Partnerships and Acquisition GSK co-led Adrestia's Series A financing alongside Ahren Innovation Capital, establishing a multi-project discovery collaboration in which each of up to five joint programmes was eligible for up to $230 million in post-option development and commercialisation milestones, plus royalties. In August 2023, Insmed Incorporated (Nasdaq: INSM) acquired Adrestia, integrating its synthetic rescue technology into Insmed's early-stage rare disease research portfolio. Further information is available at adrestia.com.

View profile
A

Alacris Theranostics

Alacris Theranostics positions itself as a systems medicine company, delivering integrated next-generation sequencing (NGS) services and bioinformatics solutions designed to translate multi-modal omics data into actionable insights for researchers, pharmaceutical partners and healthcare professionals. Based in Germany, the company's core offering spans the full omics workflow, from NGS data generation through to computational interpretation. Its bioinformatics capability is presented as central to the value proposition, enabling clients to move from raw sequencing output to clinically and scientifically meaningful results without switching vendors or platforms. The company also offers immune repertoire analysis alongside its broader genomics portfolio. A distinctive element of Alacris Theranostics' research and development work is the ModCell digital twin concept, a computational modelling approach aimed at supporting personalised medicine applications. The Alacris-CMTA platform is referenced within this context, reflecting an ambition to connect molecular profiling with precision oncology decision-making. The company's stated mission is to make comprehensive NGS services accessible across the research and pharma sectors, with a declared focus on advancing precision medicine and improving patient outcomes. Its approach emphasises customisation, on the basis that each project and each patient presents distinct challenges that standardised pipelines may not adequately address. Quality management, equality and diversity commitments, and an environmental policy statement are all cited on its public-facing communications, indicating structured internal governance. Further information is available at alacris.de.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy